Fig. 4

MiR-34c and the TGFβ pathway are involved in cisplatin sensitivity in NPC cells. a to d Cell viability was assessed 72 h after cisplatin treatment using the ATPlite assay. a Stable NP69-anti-miR-34c (or control) cells. b Stable NP460-anti-miR-34c (or control) cells. c Stable C666–1-pre-miR-34c (or control) cells. d C666–1 cells were treated simultaneously with combinations of cisplatin and SB431542 with varying doses. The data are represented as the mean ± SEM of at least three independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001. e Kaplan-Meier curve of OS based on low (<median) vs. high (>median) SOX4 expression (nuclear staining of tumour cells) using an anti-SOX4 polyclonal antibody in 25 NPC patients treated with chemoradiation (median follow-up time = 5 years). f Proposed model for the miR-449-TGFβ1-miR-34c-SOX4 pathway [12]. The red dotted line indicates that the mechanism remains unknown